{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T17:00:11Z","timestamp":1760979611381},"reference-count":93,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2004,8,1]],"date-time":"2004-08-01T00:00:00Z","timestamp":1091318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2004,8]]},"DOI":"10.1016\/j.ejca.2004.04.009","type":"journal-article","created":{"date-parts":[[2004,6,22]],"date-time":"2004-06-22T17:29:16Z","timestamp":1087925356000},"page":"1812-1824","source":"Crossref","is-referenced-by-count":23,"title":["Isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: recent trends and perspectives"],"prefix":"10.1016","volume":"40","author":[{"given":"J","family":"Rothbarth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.A.E.M","family":"Tollenaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.H.M","family":"Schellens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.W.R","family":"Nortier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.J.Schultze","family":"Kool","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.J.K","family":"Kuppen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.J","family":"Mulder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.J.H","family":"van de Velde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2004.04.009_BIB1","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0960-7404(94)90005-1","article-title":"Isolated hyperthermic liver perfusion with chemotherapy for liver malignancy","volume":"3","author":"Hafstrom","year":"1994","journal-title":"Surg. Oncol."},{"key":"10.1016\/j.ejca.2004.04.009_BIB2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000215394","article-title":"[Isolated liver perfusion in advanced metastases of colorectal cancers]","volume":"7","author":"Aigner","year":"1984","journal-title":"Onkologie"},{"key":"10.1016\/j.ejca.2004.04.009_BIB3","first-page":"1539","article-title":"Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver","volume":"82","author":"Vahrmeijer","year":"2000","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejca.2004.04.009_BIB4","first-page":"3062","article-title":"A phase I-II study of isolated hepatic perfusion using melphalan with or without tumour necrosis factor for patients with ocular melanoma metastatic to liver","volume":"6","author":"Alexander","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejca.2004.04.009_BIB5","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1200\/JCO.1998.16.4.1479","article-title":"Isolated hepatic perfusion with tumour necrosis factor and melphalan for unresectable cancers confined to the liver","volume":"16","author":"Alexander","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejca.2004.04.009_BIB6","series-title":"Hyperthermia and Oncology","first-page":"9","article-title":"Mechanisms of thermal enhancement of chemotherapeutic cytotoxicity","author":"Dahl","year":"1994"},{"key":"10.1016\/j.ejca.2004.04.009_BIB7","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000415979","article-title":"Isolated liver perfusion with MMC\/5-FU:surgical technique, pharmacokinetics, clinical results","volume":"29","author":"Aigner","year":"1988","journal-title":"Contr. Oncol."},{"key":"10.1016\/j.ejca.2004.04.009_BIB8","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/oxfordjournals.jjco.a023243","article-title":"Isolated liver perfusion with mitomycin C in the treatment of colorectal cancer metastases confined to the liver","volume":"26","author":"Marinelli","year":"1996","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.ejca.2004.04.009_BIB9","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S0039-6060(98)70200-4","article-title":"First experience and technical aspects of isolated liver perfusion for extensive liver metastasis","volume":"123","author":"Oldhafer","year":"1998","journal-title":"Surgery"},{"key":"10.1016\/j.ejca.2004.04.009_BIB10","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1067\/msy.2001.110365","article-title":"Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer","volume":"129","author":"Bartlett","year":"2001","journal-title":"Surgery"},{"key":"10.1016\/j.ejca.2004.04.009_BIB11","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/978-3-642-80460-1_11","article-title":"Isolated hepatic perfusion with tumour necrosis factor alpha and melphalan: experimental studies in pigs and phase I data from humans","volume":"147","author":"de Vries","year":"1998","journal-title":"Recent Results Cancer Res."},{"key":"10.1016\/j.ejca.2004.04.009_BIB12","first-page":"6343","article-title":"Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver","volume":"9","author":"Alexander","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejca.2004.04.009_BIB13","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/bjc.1991.466","article-title":"Increasing the effective concentration of melphalan in experimental rat liver tumours: comparison of isolated liver perfusion and hepatic artery infusion","volume":"64","author":"Marinelli","year":"1991","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejca.2004.04.009_BIB14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0009-2797(02)00014-5","article-title":"Modulation of cytostatic efficacy of melphalan by glutathione: mechanisms and efficacy","volume":"140","author":"Rothbarth","year":"2002","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ejca.2004.04.009_BIB15","doi-asserted-by":"crossref","unstructured":"Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J. Clin. Oncol. 1992, 10, 896\u2013903","DOI":"10.1200\/JCO.1992.10.6.896"},{"key":"10.1016\/j.ejca.2004.04.009_BIB16","doi-asserted-by":"crossref","unstructured":"Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer. J. Clin. Oncol. 1998, 16, 301\u2013308","DOI":"10.1200\/JCO.1998.16.1.301"},{"key":"10.1016\/j.ejca.2004.04.009_BIB17","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/bjs.4308","article-title":"Isolated hepatic perfusion with high-dose melphalan for the treatment of colorectal metastasis confined to the liver","volume":"90","author":"Rothbarth","year":"2003","journal-title":"Br. J. Surg."},{"key":"10.1016\/j.ejca.2004.04.009_BIB18","article-title":"Isolated hepatic perfusion with high dose melphalan for the treatment of uveal melanoma metastases confined to the liver","author":"Noter","year":"2003","journal-title":"Melanoma Res."},{"key":"10.1016\/j.ejca.2004.04.009_BIB19","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/978-3-642-80460-1_11","article-title":"Isolated hepatic perfusion with tumour necrosis factor alpha and melphalan: experimental studies in pigs and phase I data from humans","volume":"147","author":"de Vries","year":"1998","journal-title":"Recent Results Cancer Res."},{"key":"10.1016\/j.ejca.2004.04.009_BIB20","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1053\/ejso.1998.0623","article-title":"Isolated hepatic perfusion with extracorporeal oxygenation using hyperthermia, tumour necrosis factor alpha and melphalan","volume":"25","author":"Lindner","year":"1999","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.ejca.2004.04.009_BIB21","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1038\/bjc.1996.652","article-title":"Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study","volume":"74","author":"Nooijen","year":"1996","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejca.2004.04.009_BIB22","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/00000658-199612000-00011","article-title":"Isolated limb perfusion with tumour necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience","volume":"224","author":"Eggermont","year":"1996","journal-title":"Ann. Surg."},{"key":"10.1016\/j.ejca.2004.04.009_BIB23","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/bjs.1800830438","article-title":"Synergistic antitumour effect of recombinant human tumour necrosis factor alpha with melphalan in isolated limb perfusion in the rat","volume":"83","author":"Manusama","year":"1996","journal-title":"Br. J. Surg."},{"key":"10.1016\/j.ejca.2004.04.009_BIB24","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1200\/JCO.1996.14.10.2653","article-title":"Isolated limb perfusion with high-dose tumour necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial","volume":"14","author":"Eggermont","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejca.2004.04.009_BIB25","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1200\/JCO.1996.14.2.479","article-title":"Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumour necrosis factor, and interferon gamma: results of a tumour necrosis factor dose-escalation study","volume":"14","author":"Fraker","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejca.2004.04.009_BIB26","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1200\/JCO.1992.10.1.52","article-title":"High-dose recombinant tumour necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma","volume":"10","author":"Lienard","year":"1992","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejca.2004.04.009_BIB27","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/sj.bjc.6600707","article-title":"Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-alpha-based isolated hepatic perfusion","volume":"88","author":"van Etten","year":"2003","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejca.2004.04.009_BIB28","unstructured":"Fraker DL. Isolated hepatic perfusion (IHP) with TNF. Cambridge Symposia 11, Hilton Head, SC, March 10\u201315, 1996"},{"key":"10.1016\/j.ejca.2004.04.009_BIB29","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/bjc.1990.257","article-title":"The effect of hyperthermia in combination with melphalan on drug- sensitive and drug-resistant CHO cells in vitro","volume":"62","author":"Bates","year":"1990","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejca.2004.04.009_BIB30","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3109\/02656738509029280","article-title":"Strand break repair, DNA polymerase activity and heat radiosensitization in thermotolerant cells","volume":"1","author":"Jorritsma","year":"1985","journal-title":"Int. J. Hyperthermia"},{"key":"10.1016\/j.ejca.2004.04.009_BIB31","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1365-2184.1995.tb00049.x","article-title":"Effect of melphalan and hyperthermia on cell cycle progression and cyclin B1 expression in human melanoma cells","volume":"28","author":"Orlandi","year":"1995","journal-title":"Cell Prolif."},{"key":"10.1016\/j.ejca.2004.04.009_BIB32","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/bjc.1990.257","article-title":"The effect of hyperthermia in combination with melphalan on drug- sensitive and drug-resistant CHO cells in vitro","volume":"62","author":"Bates","year":"1990","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejca.2004.04.009_BIB33","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1038\/bjc.1996.654","article-title":"Effect of melphalan and hyperthermia on p34cdc2 kinase activity in human melanoma cells","volume":"74","author":"Orlandi","year":"1996","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejca.2004.04.009_BIB34","unstructured":"Rothbarth J, Tollenaar RA, van de Velde CJ, Mulder GJ. Hyperthermia increases melphalan efficacy in CC531 tumours implanted in rat liver in vivo [submitted]"},{"key":"10.1016\/j.ejca.2004.04.009_BIB35","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/archsurg.1986.01400110056009","article-title":"Tumouricidal effects and patient survival after hyperthermic liver perfusion","volume":"121","author":"Skibba","year":"1986","journal-title":"Arch. Surg."},{"key":"10.1016\/j.ejca.2004.04.009_BIB36","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1259\/0007-1285-58-685-63","article-title":"Thermochemotherapy with cis-platinum, CCNU, BCNU, chlorambucil and melphalan on murine marrow and two tumours: therapeutic gain for melphalan only","volume":"58","author":"Honess","year":"1985","journal-title":"Br. J. Radiol."},{"key":"10.1016\/j.ejca.2004.04.009_BIB37","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/bjc.1982.3","article-title":"Response of two mouse tumours to hyperthermia with CCNU or melphalan","volume":"45","author":"Joiner","year":"1982","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejca.2004.04.009_BIB38","first-page":"1550","article-title":"Pharmacokinetic and pharmacodynamic advantages of pirarubicin over adriamycin after intraarterial hepatic administration in the rabbit VX2 tumour model","volume":"53","author":"Munck","year":"1993","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejca.2004.04.009_BIB39","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2165\/00003088-199936060-00001","article-title":"Can pharmacokinetic monitoring improve clinical use of fluorouracil?","volume":"36","author":"Young","year":"1999","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejca.2004.04.009_BIB40","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/0959-8049(95)00214-4","article-title":"Treatment of colorectal cancer metastases confined to the liver","volume":"31A","author":"Vahrmeijer","year":"1995","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejca.2004.04.009_BIB41","doi-asserted-by":"crossref","first-page":"459","DOI":"10.7326\/0003-4819-107-4-459","article-title":"Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomised trial","volume":"107","author":"Kemeny","year":"1987","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ejca.2004.04.009_BIB42","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1200\/JCO.2000.18.2.243","volume":"18","author":"Lorenz","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejca.2004.04.009_BIB43","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.1992.10.7.1112","article-title":"Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomised trial","volume":"10","author":"Rougier","year":"1992","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejca.2004.04.009_BIB44","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1200\/JCO.1987.5.11.1836","article-title":"Tumour and liver drug uptake following hepatic artery and portal vein infusion","volume":"5","author":"Sigurdson","year":"1987","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejca.2004.04.009_BIB45","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/jso.2930550406","article-title":"Influence of portal branch ligation on the outcome of repeat dearterializations of an experimental liver tumour in the rat","volume":"55","author":"Wang","year":"1994","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.ejca.2004.04.009_BIB46","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1124\/jpet.103.049379","article-title":"Melphalan antitumour efficacy and hepatotoxicity: the effect of variable infusion duration in the hepatic artery","volume":"305","author":"Rothbarth","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejca.2004.04.009_BIB47","first-page":"1","article-title":"Hepatic blood flow: morphologic aspects and physiologic regulation","volume":"21","author":"Rappaport","year":"1980","journal-title":"Int. Rev. Physiol."},{"key":"10.1016\/j.ejca.2004.04.009_BIB48","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/hep.1840190518","article-title":"Presinusoidal and proximal intrasinusoidal confluence of hepatic artery and portal vein in rat liver: functional evidence by orthograde and retrograde bivascular perfusion","volume":"19","author":"Watanabe","year":"1994","journal-title":"Hepatology"},{"key":"10.1016\/j.ejca.2004.04.009_BIB49","first-page":"690","volume":"247","author":"Pang","year":"1988","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejca.2004.04.009_BIB50","first-page":"339","article-title":"Retrograde perfusion to probe the heterogeneous distribution of hepatic drug metabolizing enzymes in rats","volume":"216","author":"Pang","year":"1981","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejca.2004.04.009_BIB51","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ejso.2003.08.004","article-title":"An experimental minimally invasive perfusion technique for the treatment of liver metastases","volume":"29","author":"Rothbarth","year":"2003","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.ejca.2004.04.009_BIB52","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1124\/jpet.102.037895","article-title":"Reduced liver uptake of arterially infused melphalan during retrograde rat liver perfusion with unaffected liver tumour uptake","volume":"303","author":"Rothbarth","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejca.2004.04.009_BIB53","first-page":"579","article-title":"Reduction of systemic drug exposure after hepatic arterial infusion of doxorubicin with complete hepatic venous isolation and extracorporeal chemofiltration","volume":"114","author":"Curley","year":"1993","journal-title":"Surgery"},{"key":"10.1016\/j.ejca.2004.04.009_BIB54","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1200\/JCO.1994.12.12.2723","article-title":"Percutaneous hepatic vein isolation and high-dose hepatic arterial infusion chemotherapy for unresectable liver tumours","volume":"12","author":"Ravikumar","year":"1994","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejca.2004.04.009_BIB55","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/978-3-642-80460-1_8","article-title":"Percutaneous isolated liver chaemoperfusion for treatment of unresectable malignant liver tumours: technique, pharmacokinetics, clinical results","volume":"147","author":"Ku","year":"1998","journal-title":"Recent Results Cancer Res."},{"key":"10.1016\/j.ejca.2004.04.009_BIB56","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1097\/00000658-199812000-00007","article-title":"Isolated hypoxic hepatic perfusion with tumour necrosis factor-alpha, melphalan, and mitomycin C using balloon catheter techniques: a pharmacokinetic study in pigs","volume":"228","author":"van Ijken","year":"1998","journal-title":"Ann. Surg."},{"key":"10.1016\/j.ejca.2004.04.009_BIB57","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1001\/archsurg.138.3.325","article-title":"Percutaneous isolated hepatic perfusion for chemotherapy: a phase 1 study","volume":"138","author":"Savier","year":"2003","journal-title":"Arch. Surg."},{"key":"10.1016\/j.ejca.2004.04.009_BIB58","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1148\/radiographics.22.1.g02ja08141","article-title":"Congenital and acquired anomalies of the portal venous system","volume":"22","author":"Gallego","year":"2002","journal-title":"Radiographics"},{"key":"10.1016\/j.ejca.2004.04.009_BIB59","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/(SICI)1097-0142(19960315)77:6<1073::AID-CNCR11>3.0.CO;2-Z","article-title":"Whole blood harvested after granulocyte-colony stimulating factor (Neupogen) mobilization, and reinfused unprocessed after high-dose melphalan treatment, accelerates hematopoietic recovery in patients with multiple myeloma","volume":"77","author":"Raina","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2004.04.009_BIB60","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM200009283431302","article-title":"Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group","volume":"343","author":"Saltz","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejca.2004.04.009_BIB61","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(98)02309-5","article-title":"Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer","volume":"352","author":"Cunningham","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2004.04.009_BIB62","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(98)03085-2","article-title":"Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer","volume":"352","author":"Rougier","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2004.04.009_BIB63","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","article-title":"Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial","volume":"355","author":"Douillard","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2004.04.009_BIB64","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","article-title":"Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer","volume":"18","author":"de Gramont","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejca.2004.04.009_BIB65","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.2000.18.1.136","article-title":"Phase III multicenter randomised trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer","volume":"18","author":"Giacchetti","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejca.2004.04.009_BIB66","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","article-title":"FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomised GERCOR Study","volume":"22","author":"Tournigand","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejca.2004.04.009_BIB67","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1023\/A:1008213732429","article-title":"Oxaliplatin: a review of preclinical and clinical studies","volume":"9","author":"Raymond","year":"1998","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejca.2004.04.009_BIB68","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/oxfordjournals.annonc.a010489","article-title":"Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines","volume":"7","author":"Machover","year":"1996","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejca.2004.04.009_BIB69","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1021\/jm00123a038","article-title":"Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity","volume":"32","author":"Hertzberg","year":"1989","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejca.2004.04.009_BIB70","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/oxfordjournals.annonc.a059109","article-title":"Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials","volume":"6","author":"Chabot","year":"1995","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejca.2004.04.009_BIB71","first-page":"13","article-title":"Pharmacokinetics and safety profile of oxaliplatin","volume":"25","author":"Extra","year":"1998","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ejca.2004.04.009_BIB72","first-page":"4","article-title":"Oxaliplatin: mechanism of action and antineoplastic activity","volume":"25","author":"Raymond","year":"1998","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ejca.2004.04.009_BIB73","first-page":"252","article-title":"Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGRF)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC)","volume":"22","author":"Cunningham","year":"2003","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ejca.2004.04.009_BIB74","volume":"22","author":"Hurwitz","year":"2003","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ejca.2004.04.009_BIB75","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/00000658-199909000-00008","article-title":"Regional versus systemic delivery of recombinant vaccinia virus as suicide gene therapy for murine liver metastases","volume":"230","author":"Gnant","year":"1999","journal-title":"Ann. Surg."},{"key":"10.1016\/j.ejca.2004.04.009_BIB76","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/sj.gt.3300362","article-title":"Isolated-organ perfusion for local gene delivery: efficient adenovirus-mediated gene transfer into the liver","volume":"4","author":"de Roos","year":"1997","journal-title":"Gene Ther."},{"key":"10.1016\/j.ejca.2004.04.009_BIB77","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1006\/mthe.2001.0444","article-title":"Intratumoural adenovirus-mediated suicide gene transfer for hepatic metastases from colorectal adenocarcinoma: results of a phase I clinical trial","volume":"4","author":"Sung","year":"2001","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejca.2004.04.009_BIB78","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1089\/hum.1997.8.8-985","article-title":"Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine","volume":"8","author":"Crystal","year":"1997","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ejca.2004.04.009_BIB79","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1089\/10430340150218369","article-title":"E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumours","volume":"12","author":"Habib","year":"2001","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ejca.2004.04.009_BIB80","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0006-2952(99)00094-5","article-title":"Melphalan resistance and photoaffinity labelling of P-glycoprotein in multidrug-resistant Chinese hamster ovary cells: reversal of resistance by cyclosporin A and hyperthermia","volume":"58","author":"Larrivee","year":"1999","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejca.2004.04.009_BIB81","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000041037","article-title":"Down-regulation of CD98 in melphalan-resistant myeloma cells with reduced drug uptake","volume":"103","author":"Harada","year":"2000","journal-title":"Acta Haematol."},{"key":"10.1016\/j.ejca.2004.04.009_BIB82","doi-asserted-by":"crossref","first-page":"445","DOI":"10.3109\/10409239509083491","article-title":"The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance","volume":"30","author":"Hayes","year":"1995","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"10.1016\/j.ejca.2004.04.009_BIB83","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3109\/07357909609018891","article-title":"Glutathione and drug resistance","volume":"14","author":"Schroder","year":"1996","journal-title":"Cancer Invest."},{"key":"10.1016\/j.ejca.2004.04.009_BIB84","first-page":"4900","article-title":"Expression of a rat glutathione-S-transferase complementary DNA in rat mammary carcinoma cells: impact upon alkylator-induced toxicity","volume":"53","author":"Schecter","year":"1993","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejca.2004.04.009_BIB85","first-page":"4709","article-title":"Lack of glutathione conjugation of melphalan in the isolated in situ liver perfusion in humans","volume":"56","author":"Vahrmeijer","year":"1996","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejca.2004.04.009_BIB86","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1093\/jnci\/93.19.1473","article-title":"In vitro evidence for homologous recombinational repair in resistance to melphalan","volume":"93","author":"Wang","year":"2001","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ejca.2004.04.009_BIB87","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S1097-2765(00)80078-7","article-title":"XRCC2 and XRCC3, new human Rad51-family members, promote chromosome stability and protect against DNA cross-links and other damages","volume":"1","author":"Liu","year":"1998","journal-title":"Mol. Cell."},{"key":"10.1016\/j.ejca.2004.04.009_BIB88","first-page":"2569","article-title":"Alkylator resistance in human B lymphoid cell lines: (2). Increased levels of topoisomerase II expression and function in a melphalan-resistant B-CLL cell line","volume":"20","author":"Pu","year":"2000","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ejca.2004.04.009_BIB89","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/j.bcp.2003.12.038","article-title":"Immunohistochemical detection of melphalan-DNA adducts in colon cancer cells in vitro and human colorectal liver tumours in vivo","volume":"67","author":"Rothbarth","year":"2004","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejca.2004.04.009_BIB90","first-page":"325","article-title":"Colorectal liver metastasis thymidylate synthase staining correlates with response to hepatic arterial floxuridine","volume":"5","author":"Davies","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejca.2004.04.009_BIB91","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1056\/NEJMoa021967","article-title":"A gene-expression signature as a predictor of survival in breast cancer","volume":"347","author":"van de Vijver","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejca.2004.04.009_BIB92","article-title":"Phase III study of bolus 5-Fluorouracil (5-FU)\/ Folinic Acid (FA)(Mayo) Vs. weekly high-dose 24h 5-FU infusion\/ FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC)","author":"Grothey","year":"2002","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ejca.2004.04.009_BIB93","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/BF01655820","article-title":"Rationale and indications for perfusion in liver tumours: current data","volume":"11","author":"Schwemmle","year":"1987","journal-title":"World J. Surg."}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804904003442?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804904003442?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T13:59:57Z","timestamp":1585835997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804904003442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8]]},"references-count":93,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2004,8]]}},"alternative-id":["S0959804904003442"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2004.04.009","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2004,8]]}}}